Ipsen – 2026Q2 Earnings
Latest Financial Earnings Summary Ipsen reported its financial results for the first half of 2026 (covering the second quarter and six-month period ending June 30, 2026): Revenue Breakdown by Therapeutic Segment and Geography Therapeutic Franchise & Product Breakdown (H1 2026 Total Sales: €2,190.2 million) Geographical Revenue Breakdown Operational Changes, Catalysts, and Future Outlook Key Operational […]
Ipsen – supply chain and competitions
Market Position and Market Share Ipsen S.A. is a French mid-cap global specialty biopharmaceutical company with FY 2025 total sales of €3,675.9m (an 8.1% reported growth and 10.9% at constant exchange rates) and a core operating margin of 35.2%.The company concentrates on three therapeutic franchises: Oncology (representing approximately 67% to 70% of total sales), Neuroscience […]
Ipsen – history and business model
Corporate History Foundational and Primary Care Era (1929–1975) Founded in 1929 by Henri Beaufour in Dreux, France, the company began as Laboratoires Beaufour, launching digestive products like Smecta. Throughout this phase, the business functioned as a regional family-run pharmaceutical enterprise primarily serving primary healthcare markets. Specialty Care and International Expansion (1976–2005) Under the leadership of […]